University defends pharma-funded report from MSF critics
13th March 2014
A leading UK university has reacted with bemusement to criticism from Medecins Sans Frontieres about a report it has published regarding the financing of future research at a time when innovative drugmakers are struggling to get what they perceive are fair prices for their therapies.
The UCL School of Pharmacy has issued a report, funded mainly by Bayer and Novartis, which expresses concern relating to the use of unlicensed products as comparators in cost effectiveness appraisals. While claiming that the National Institute for Health and Care Excellence “has many positive achievements to its credit”, the report is broadly critical of the agency’s methodologies and expresses fears about “an increased emphasis on saving cash” to the detriment of providing care for patients.